Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Sorafenib is an approved chemotherapeutic for hepatocellular carcinoma (HCC).
• Digitoxin, a cardiotonic drug, shows anticancer effects in various cancers but not yet in HCC.
• Investigating novel therapeutic combinations is crucial for improving HCC treatment outcomes.

Purpose of the Study:

• To evaluate the combined efficacy of sorafenib and digitoxin in HCC treatment.
• To elucidate the molecular mechanisms underlying the synergistic effects of this drug combination.
• To assess the impact on HCC cell proliferation, death, and migration.

Main Methods:

• Utilized MTT assays for cell viability.
• Employed acridine orange/ethidium bromide staining for cell death assessment.
• Conducted scratch wound healing assays to evaluate cell migration.
• Performed western blot analysis to measure protein expression levels of ERK, HIF-1α, HIF-2α, and VEGF.

Main Results:

• Sorafenib and digitoxin synergistically inhibited HCC cell viability.
• The combination treatment did not significantly affect cell migration.
• Combinatorial therapy led to synergistic suppression of extracellular signal-regulated kinase (ERK) activity.
• Expression of hypoxia-inducible factor 1-alpha (HIF-1α), hypoxia-inducible factor 2-alpha (HIF-2α), and vascular endothelial growth factor (VEGF) was synergistically downregulated.

Conclusions:

• Sorafenib and digitoxin exhibit synergistic anticancer effects in HCC cell lines.
• The combination therapy potentially acts by suppressing ERK and hypoxia signaling pathways.
• This combination demonstrates promise for future HCC therapeutic strategies.